Getting back on track: control of covid-19 outbreaks in the communityBMJ 2020; 369 doi: https://doi.org/10.1136/bmj.m2484 (Published 25 June 2020) Cite this as: BMJ 2020;369:m2484
- 1Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK
- 2School of Health Sciences, City, University of London, London, UK
- Correspondence to: P Roderick
Historically, England’s system of communicable disease control has relied on close cooperation between local health services and authorities. General practitioners, NHS and public health laboratories, and local public health officers play key roles, backed by legal notification requirements.
That local system has gradually been eroded over several decades. (box 1) But instead of prioritising and rebuilding this system at the start of this epidemic, the government has created a separate system which steers patients away from GPs, avoids local authorities, and relies on commercial companies and laboratories to track, test, and contact trace. The ad hoc parallel system in England has three components:
Erosion of local communicable disease control in England
At its height, local communicable disease control was supported by more than 60 national, regional, and local public health laboratories. The service was strengthened from 1977-2002 by the creation of the Communicable Disease Surveillance Centre in Colindale.
Erosion began after NHS reorganisation in 1974 and continued when the Public Health Laboratory Service Board was abolished in 2003 and its local laboratories transferred to NHS trusts, at the same time as communicable disease control was centralised in the Health Protection Agency.
In 2012, the Health and Social Care Act abolished locally based bodies in England and carved public health functions out of the NHS. Public Health England was set up as an executive agency to fulfil the government’s duty to protect the public from disease, with only nine laboratories and eight regional centres. Local authorities were charged with improving public health. Each local authority was required, acting jointly with the secretary of state, to appoint a director of public health, with responsibility for exercising the authority’s public health functions.RETURN TO TEXT
Covid-19 primary care programme which, until 29 May 2020, did not include information on need to notify suspected cases to local authorities
Centralised testing programme that relies heavily on private companies
Centrally led contact tracing system that uses commercial call centres and may in future use a mobile phone app.
We question why the government has created this ad hoc parallel system when a straightforward, if weakened, system already existed. In addition, we are concerned by apparent failings in this parallel system. The notification system (table 1) seems to have been mishandled from the beginning, and many suspected cases will have been missed as a result. Outsourced private testing services have been given the bulk of government business, with no clear public health standards. There is also a lack of clarity on where the results are being sent.
Notification of suspected cases
SARS-CoV-2 was declared a serious and imminent threat to public health on 10 February 2020,1 but covid-19 was added to the list of notifiable diseases only on 5 March.2 From the outset, the notification system was inadequate.
NHS 111 covid-19 call centres were hastily set up. Symptomatic patients were advised to stay at home and not contact their GPs or NHS 111 initially,3 and thereafter to contact NHS 111 online. This will have prevented rapid reporting of suspected cases. A covid-19 clinical assessment service was also set up to receive and possibly reclassify referrals after NHS 111 triaging, using retired and locum or sessional GPs instead of general practices. It is not known whether registered medical practitioners working in NHS 111 or the assessment service notified any suspected cases.
NHS guidance4 did not alert GPs to the need to inform local authorities of suspected cases. It advised GPs to inform Public Health England (PHE) of symptomatic cases and then only in specified settings or unusual scenarios. The guidance also wrongly implied that the requirements relating to notifiable diseases apply only to confirmed cases. These failings were only partially rectified in new guidance dated 29 May 2020.5 PHE’s guidance wrongly implies that local authorities do not need to be notified of suspected cases.6
Centralised and commercially run tests
A public health approach to testing requires a clear purpose, systematic delivery and data flows, informed participation, quality assurance, equity, and ethical oversight to build trust. Decisions should be safeguarded from political and commercial interference.7 The testing programme announced by the government on 4 April 20208 with its “five pillars” falls well short of what is required.
Instead of focusing on increasing capacity in PHE and NHS laboratories, which report results to PHE through its second generation surveillance system, the government designated these laboratories as “pillar 1” for people with a clinical need and health and care workers and set up a separate, centralised, and commercially based “pillar 2” for the wider population.
Daily numbers of pillar 1 tests have levelled off, and numbers of pillar 2 tests now tend to exceed those for pillar 1.9 They include in-person tests, which are counted when samples are taken at testing stations at about 50 regional sites and mobile testing units run by the army. Testing kits posted out to people at home and elsewhere are counted on dispatch,10 and it is not known how many are actually used. Numbers have increased dramatically on some occasions when the government has been trying to reach preset targets for testing.11
The president of the Institute of Biomedical Science has described creating this new additional structure as “perverse,” competing with NHS laboratories and freezing them out.12
Pillar 2 is based on contracts with commercial companies. Very few appear on the government’s contracts finder website. It seems from the list of data processors,13 which has changed frequently, that testers at regional sites are provided by Sodexo and Boots; some sites are operated by Deloitte. Serco, G4S, and Levy provide facilities management. Randox provides home testing kits, the logistics for which are provided by Amazon.
Pillar 2 samples are analysed by the four new “lighthouse labs,” which involve AstraZeneca and GlaxoSmithKline (box 2), even though both state that “diagnostic testing is not part of either company’s core business.”1516 Randox analyses the samples from its home test kits, with a contract for £133m (€150m; $165m).17 This compares with the £86.9m provided to PHE for infectious disease, surveillance, and outbreak management in 2018-19.18 In all, 67 000 Randox tests are reported to have been sent to the US for analysis because of lack of capacity, but 29 500 results were found to be invalid and needed to be redone.19
Milton Keynes—managed by UK Biocentre, the largest facility in the UK for storing and processing biological samples. It is the trading subsidiary of the charity UK Biobank
Alderley Park is a life science campus with a dedicated lab for covid-19 analysis led by Medicines Discovery Catapult, which was set up as a limited company with a grant from Innovate UK to support drug companies, contract research organisations, and diagnostic businesses operating in the health sector
Glasgow—the lab is led by the University of Glasgow at the city’s Queen Elizabeth University Hospital. It is supported by the Scottish Government, BioAscent Discovery (a provider of integrated drug discovery services), and the University of Dundee
Cambridge—a collaboration between AstraZeneca, GSK, and the University of Cambridge’s Anne McLaren laboratoryRETURN TO TEXT
According to the government,13 results of non-Randox tests are sent to the National Pathology Exchange (NPEx) hosted by Calderdale and Huddersfield NHS Foundation Trust. NPEx links them to test registration and passes results to NHS Digital and to the NHS Business Services Authority, which sends results to those who have been tested. The government also states that Palantir analyses anonymised data.13
The strategy has three further pillars. Pillar 3 is mass antibody testing. Pillar 4 is a programme of serology and swab testing for national surveillance supported by PHE, the Office for National Statistics, UK Biobank, universities, and other partners. The aim of Pillar 5 is to build a British diagnostics industry, with the short term aim of supplying the other pillars.
Feedback of results
It is unclear what happens to many test results, in particular whether they are fed back to individual patients’ GPs. Several hundred thousand tests are reported not to have been linked to NHS records, missing confirmed cases.20 There is also no indication whether results are made available to staff doing local contract tracing. The chief medical officer for England is reported to have apologised to local authorities for not having detailed data from tests conducted by Deloitte.21 It is unclear whether PHE has timely access to test outcomes.
Further problems have arisen in relation to reporting numbers of tests and results in national statistics, prompting two letters to the secretary of state for health and social care from David Norgrove, chair of the UK Statistics Authority.2223 The second suggested that the statistics should enable an understanding of the epidemic and help manage the testing programme but pointed out that “the statistics and analysis serve neither purpose well” and that the main aim seemed to be to claim the largest possible numbers of tests.
Centralised and commercially run contact tracing
Contact tracing is a local activity. Local authorities know their community, and tracing requires feet on the ground. But the tracing programme announced by the secretary of state on 23 April 202024 is centralised, using call centres operated by Serco and other companies with thousands of newly recruited call handlers. The programme may not be fully operational until September.25 The NHS covid-19 app, which had been touted as key to contact tracing, has now been abandoned.
It is unclear how the contact tracing programme will operate, as outbreak management plans are yet to be produced. The government’s guidance does not mention GPs or local directors of public health.26 It is not known whether, how, or to whom suspected cases will be notified. Inefficiency, data quality issues, local data access difficulties, and unnecessary expense are inevitable.
Details such as full postcodes, and age and sex of suspected and confirmed cases are essential for monitoring outbreaks in a local authority area and identifying clusters. However, local authorities do not have live access to this information and are instead sent aggregated data. This approach, combined with the failures to require notification of suspected cases and to undertake community testing, has further hampered outbreak control. Instead of restoring local data flows, the government is attempting to create a population surveillance system through the new Joint Biosecurity Centre.27 The centre will receive data from numerous sources, including NHS data through the portal of NHSX’s covid-19 data store reference library. Over 50 datasets are being integrated and harmonised by private data companies Palantir and Faculty to create a “single source of truth.”28
Making it work
Immediate steps should be taken to ensure that registered medical practitioners within NHS 111, the covid-19 assessment service, and general practice notify local authorities of suspected cases. Outbreak management plans should put local directors of public health in control of contact tracing, coordinated rather than led by PHE. The capacity of the NHS 111 covid-19 call centres and the assessment service should be immediately reintegrated into primary care and practices resourced to resume care. Official advice to those with covid-19 symptoms should be amended to direct them to contact a GP or NHS 111.
These steps, however, are remedial. They do not amount to a coherent and adequate public health response to the epidemic in England. Such a response requires local authorities, NHS, and PHE laboratories to be sufficiently resourced to take the lead on contact tracing and testing, and general practices being resourced to support patients, under central coordination. Parliament has given the secretary of state the powers to enable this to happen, and we urge him to exercise them.
In the longer term, the abysmal response of the government to the epidemic has served to underline the need for legislation to rebuild and reintegrate a strong local communicable disease control system.
England’s established system of local communicable disease control has been eroded over several decades
In response to covid-19 the government has created a parallel system which steers patients away from GPs and relies on commercial companies for testing and contact tracing
Many suspected cases will have been missed because of mishandling of the notification system
NHS 111 covid-19 call centres and the covid-19 clinical assessment service should be reintegrated immediately into primary care and practices resourced to resume care
Contact tracing and testing should be led by local authorities and coordinated nationally
England must rebuild and reintegrate its local communicable disease control system
Contributors and sources: PR has over 30 years’ experience as a lawyer, is co-author of the NHS Reinstatement Bill, and has written extensively on the Health and Social Care Act. AMP has 30 years of experience of researching public health policy and the privatisation of the NHS and long term care. She is a member of Independent SAGE; the views expressed here are her own. AM is a perinatal epidemiologist and statistician with over 40 years of experience of researching public health and health service policy. PR researched the statutory provisions. All authors researched the operation of the notification system in practice and the testing programme. AM and PR researched the history of local communicable disease control. PR wrote the first draft of the article and all authors were involved in further drafting and editing. We gratefully acknowledge helpful discussions with several local public health practitioners and GPs during the preparation of this article.
Competing interests: We have read and understood BMJ policy on declaration of interests and have no relevant interests to declare.
Provenance and peer review: Not commissioned; externally peer reviewed.
This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage